Safety and Efficacy of Patient Controlled Analgesia Using the Sublingual Sufentanil Tablet System (SSTS) in a Fast Track Rehabilitation Program After Total Knee Arthroplasty

Postoperative Pain Clinical Trial

— Zalviso  

Official title:

Safety and Efficacy of Patient Controlled Analgesia Using the Sublingual Sufentanil Tablet System (SSTS) in a Fast Track Rehabilitation Program After Total Knee Arthroplasty

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04432428
• Other study ID #: 2019/1741
• Status: Completed
• Phase: Phase 4
• Start date: May 26, 2020
• Est. completion date: September 19, 2021

Study information

• Verified date: January 2020
• Source: University Hospital, Ghent
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The sufentanil sublingual tablet system (SSTS) is an innovative patient-controlled analgesia (PCA) device for the management of acute moderate to severe postoperative pain in hospital settings in adult patients.

The SSTS is non-invasive and imposes no restrictions on patient mobility, which renders it particularly suitable for clinical conditions where early mobilization is a key component of successful surgical outcome.

The present study tests the hypothesis that SSTS is an efficient and safe analgesic technique allowing fast track rehabilitation after total knee arthroplasty in a prospective cohort design.

Description:

Total knee arthroplasty is one of the most common major procedures performed today with a significant impact on health care budgets. Fast track rehabilitation programmes are being developed to control hospitalization costs associated with this procedure. Interestingly, such pathway controlled fast track programs also appear to enhance functional recovery and to reduce complications. These beneficial effects are mainly attributed to the practice of rapid mobilization and early intensified physiotherapy which can only be achieved with effective analgesic techniques.

Current PCA techniques - predominantly morphine based - are the gold standard for this purpose but they involve intravenous access and a programmable computer system requiring close supervision. Reported shortcomings are systems failure leading to analgesic gaps, drug errors and restrictions in mobility since patients are tethered to IV poles. The SSTS may overcome these limitations because the opioid used, sufentanil, has a more predictable time of onset, the delivery system does not require programming, and the device does not limit patient's mobility. It retains the benefits of potent analgesia as well as patient empowerment and is particularly suited to target the analgesic effect precisely to the level required in physiotherapeutic sessions.

The present study will test the hypothesis that SSTS is an efficient and safe analgesic technique allowing fast track rehabilitation after total knee arthroplasty in a prospective cohort design.

The study will focus on the efficiency of STSS which is defined as 75% or more of the treated patients proves NRS score less than 4 during 48 hours postoperatively, additionally to the basic pain treatment (paracetamol and NSAID).

The STSS will allow the patient tot take a maximum of 3 doses in one hour. Treatment with the STSS is continued over a period of 48 hours or if necessary up to 72 hours.

During this period the patients pain en parameters will be monitored closely.

The maximum administered total dose of Zalviso will not exceed 1.2mg.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: September 19, 2021
• Est. primary completion date: August 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 75 Years

Eligibility

Inclusion Criteria:

• Male and female patients between 40-75 years old

• Able to give consent

• Scheduled of elective knee arthroplasty with a fast rehabilitation program

• Able to understand PCA principle and capable to operate SSTS device

Exclusion Criteria:

• Outside age range

• Contra indication for anti-inflammatory drugs

• Revision total knee arthroplasty

• history of substance abuse,

• pregnancy,lactation

• severe hepatic impairment (INR>1,5 and/or AST/ALT above x3 highest normal value),

• sleep apnea (documented by sleep laboratory study),

• severe chronic kidney disease (eGFR<30 mL/min/1.73 m2),

• severe and very severe COPD (GOLD III and IV)

• opioid tolerance (use of >15mg oral morphine equivalent per day within the past 3 months),

• chronic pain conditions necessitating gabapentinoids, steroids or anti-inflammatory drugs

• hypersensitivity to sufentanil

• significant respiratory depression (need for outpatient supplemental oxygen therapy),

• participation in another clinical trial

Related Conditions & MeSH terms

• Pain, Postoperative
• Postoperative Pain

Intervention

Drug:
• Sufentanil Sublingual Tablet
all patients will receive tablets for sublingual use, containing 15 microgram of sufentanil. The sufentanil tablets come in a cartridge (40 tablets) and are administered with a special patient-controlled device that uses thumb tag recognition. max dose per hour : 3 tablets of 15µg sufentanil

Locations

Country	Name	City	State
Belgium	University Hospital Ghent	Ghent	Oost-Vlaanderen

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Ghent

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total time NRS<4	cumulative time that patient had NRS<4	from end of surgery until 48 hours postoperatively
Secondary	length of hospital stay	amount of days that patient was admitted to the hosptial	from hospital admission until hospital discharge, up to 1 week post-operatively
Secondary	Incidence of the side effect nausea	Incidence of the side effect nausea with a simple scale (none, mild, moderate, severe)	from end of surgery until 72 hours postoperatively
Secondary	Incidence of the side effect vomiting	Incidence of the side effect vomiting with a simple scale (none, mild, moderate, severe)	from end of surgery until 72 hours postoperatively
Secondary	Incidence of the side effect itching	Incidence of the side effect itching with a simple scale (none, mild, moderate, severe)	from end of surgery until 72 hours postoperatively
Secondary	Incidence of the side effect drowsiness	Incidence of the side effect drowsiness with a simple scale (none, mild, moderate, severe)	from end of surgery until 72 hours postoperatively
Secondary	Incidence of the side effect constipation	Incidence of the side effect constipation with a simple scale (none, mild, moderate, severe)	from end of surgery until 72 hours postoperatively
Secondary	Oxygen desaturation	Oxygen desaturation	from end of surgery until 72 hours postoperatively
Secondary	patient satisfaction with Zalviso PCA	patient satisfaction assessed with patient ease of care questionnaire	after discontinuation of study medication, up to 72 hrs after start of the study medication
Secondary	health care worker satisfaction with the patients pain treatment with Zalviso PCA	health care worker satisfaction assessed with nurse/physical therapist ease of care questionnaire	after patients discontinuation of study medication, up to 1 week after stop study medication
Secondary	consumption of study medication	total amount of study medication that was administered	from start administration of study medication until end of administration of study medication, up to a maximum of 72 hrs
Secondary	Level of analgesia during physiotherapy	Level of analgesia during physiotherapy assessed with NRS scale	from start until end of physiotherapy session, up to 2 days post-operatively